drugset / Trial / NCT01714037
A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC]
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Part A of this study will investigate the Maximum Tolerated Dose of Debio 0932 in combination with standard of care chemotherapy for the first- and second-line treatment of advanced NSCLC.
Timeline
- Start
- 2012-08
- Primary completion
- 2014-11
- Completion
- 2014-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CUDC-305 | Small molecule | 250 mg | Oral |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Background | Docetaxel | Small molecule | 60 mg/m2 | — |
| Background | Docetaxel | Small molecule | 75 mg/m2 | — |
| Background | Gemcitabine | Small molecule | 1250 mg/m2 | — |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | — |